Synonyms: L-627 | LJC10,627 | Omegacin® | RPX2003
biapenem is an approved drug
Compound class:
Synthetic organic
|
|
No information available. |
Summary of Clinical Use ![]() |
Biapenem is administered intravenously. It has been approved in Japan since 2001 (trade name Omegacin®) and in India since 2021, where it is indicated for the treatment of intra-abdominal infections, and complicated infections of the respiratory and urinary tracts [3]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01772836 | Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination | Phase 1 Interventional | Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | ||
NCT01702649 | Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects | Phase 1 Interventional | Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) |